TRENDS IN INFECTIVE ENDOCARDITIS INCIDENCE, CHARACTERISTICS, AND VALVE REPLACEMENT IN PATIENTS WITH OPIOID USE DISORDERS IN THE UNITED STATES FROM 2005 TO 2014

2019 ◽  
Vol 73 (9) ◽  
pp. 1968 ◽  
Author(s):  
Makoto Mori ◽  
Kelly Brown ◽  
Syed Usman Bin Mahmood ◽  
Arnar Geirsson ◽  
Abeel Mangi
Keyword(s):  
United States ◽  
Infective Endocarditis ◽  
Valve Replacement ◽  
The United States ◽  
Opioid Use ◽  
Opioid Use Disorders

scholarly journals 923Lactococcus garvieae infective endocarditis requiring valve replacement: First case in the United States

2014 ◽  
Vol 1 (suppl_1) ◽  
pp. S267-S267 ◽  
Author(s):  
Calden Sharngoe ◽  
Tasaduq Fazili ◽  
Waleed Javaid ◽  
Timothy Endy ◽  
Mark Polhemus
Keyword(s):  
United States ◽  
Infective Endocarditis ◽  
Valve Replacement ◽  
The United States ◽  
First Case

Overview

2020 ◽  
pp. 121-138
Author(s):  
Yngvild Olsen ◽  
Anika A. H. Alvanzo ◽  
Jarratt D. Pytell
Keyword(s):  
Public Health ◽  
United States ◽  
The United States ◽  
Health Impacts ◽  
Opioid Use ◽  
The Us ◽  
Significant Public Health ◽  
History Of ◽  
Opioid Use Disorders ◽  
Barriers To Use

Substance use disorders (SUDs) are a significant cause of morbidity and mortality in the United States. In spite of the significant public health impacts of SUDs, medications approved by the US Food and Drug Administration (FDA) are underutilized for the treatment of SUDs. This chapter reviews the history of FDA-approved medications for alcohol, nicotine, and opioid use disorders and provides some background on barriers to use of these medications to treat patients with SUDs. Suggestions are provided to guide clinicians on a path forward to reduce these barriers and increase the use of FDA-approved medications for the treatment of SUDs.

scholarly journals Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study

2020 ◽  
Author(s):  
Joshua A Barocas ◽  
Golnaz Eftekhari Yazdi ◽  
Alexandra Savinkina ◽  
Shayla Nolen ◽  
Caroline Savitzky ◽  
...  
Keyword(s):  
United States ◽  
Infective Endocarditis ◽  
Mortality Rate ◽  
Population Level ◽  
Risk Groups ◽  
The United States ◽  
Published Data ◽  
Opioid Epidemic ◽  
Opioid Use ◽  
Behavior Profiles

Abstract Background The expansion of the US opioid epidemic has led to significant increases in infections, such as infective endocarditis (IE), which is tied to injection behaviors. We aimed to estimate the population-level IE mortality rate among people who inject opioids and compare the risk of IE death against the risks of death from other causes. Methods We developed a microsimulation model of the natural history of injection opioid use. We defined injection behavior profiles by both injection frequency and injection techniques. We accounted for competing risks of death and populated the model with primary and published data. We modeled cohorts of 1 million individuals with different injection behavior profiles until age 60 years. We combined model-generated estimates with published data to project the total expected number of IE deaths in the United States by 2030. Results The probabilities of death from IE by age 60 years for 20-, 30-, and 40-year-old men with high-frequency use with higher infection risk techniques compared to lower risk techniques for IE were 53.8% versus 3.7%, 51.4% versus 3.1%, and 44.5% versus 2.2%, respectively. The predicted population-level attributable fraction of 10-year mortality from IE among all risk groups was 20%. We estimated that approximately 257 800 people are expected to die from IE by 2030. Conclusions The expected burden of IE among people who inject opioids in the United States is large. Adopting a harm reduction approach, including through expansion of syringe service programs, to address injection behaviors could have a major impact on decreasing the mortality rate associated with the opioid epidemic.

Sign in / Sign up

Export Citation Format

Share Document